In pharmaceutical research, it seems like a small eternity passes before a medication is finally approved for sale, following long years of trials and testing. This year, Daiichi Sankyo, a leading global pharmaceutical company, has announced that its latest product Edoxaban, has finally made its entrance in some European pharmaceutical markets. At the moment, the Japanese company is about to pave the way for market introduction in Italy. Its Italian affiliate Daiichi Sankyo Italia SpA is eagerly awaiting the new product for the treatment of atrial fibrillation conditions and venous thromboembolism.
Webcode:
To read an article from the print magazine online, please enter the web code below, which can be found in the magazine under the article.
